Electra Therapeutics (NASDAQ:ETRA – Get Free Report) announced its earnings results on Thursday. The company reported ($3.47) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.76) by ($1.71), Zacks reports.
Electra Therapeutics Trading Down 3.6%
Electra Therapeutics stock traded down $0.34 during trading hours on Thursday, reaching $9.11. 545,248 shares of the stock were exchanged, compared to its average volume of 473,022. Electra Therapeutics has a twelve month low of $6.86 and a twelve month high of $15.50.
Analyst Upgrades and Downgrades
Several brokerages have recently commented on ETRA. Zacks Research raised shares of Electra Therapeutics to a “hold” rating in a report on Wednesday, October 14th. HC Wainwright began coverage on Electra Therapeutics in a research note on Monday, October 26th. They issued a “buy” rating and a $30.00 price target for the company. Cantor Fitzgerald initiated coverage on Electra Therapeutics in a research report on Tuesday, October 13th. They set an “overweight” rating on the stock. TD Cowen assumed coverage on Electra Therapeutics in a research note on Tuesday, October 13th. They set a “buy” rating on the stock. Finally, JPMorgan Chase & Co. began coverage on Electra Therapeutics in a research note on Thursday, October 22nd. They set an “overweight” rating and a $36.00 price objective on the stock. One research analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating and one has given a Hold rating to the stock. According to MarketBeat, the stock presently has an average rating of “Buy” and an average target price of $33.50.
View Our Latest Report on Electra Therapeutics
Insider Activity at Electra Therapeutics
In other news, Director Orbimed Advisors Llc purchased 1,333,333 shares of the business’s stock in a transaction dated Monday, September 21st. The stock was bought at an average price of $15.00 per share, with a total value of $19,999,995.00. Following the acquisition, the director owned 5,126,891 shares in the company, valued at approximately $76,903,365. The trade was a 35.15% increase in their position. The acquisition was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, Director Carl L. Gordon purchased 1,333,333 shares of Electra Therapeutics stock in a transaction that occurred on Monday, September 21st. The shares were purchased at an average price of $15.00 per share, for a total transaction of $19,999,995.00. Following the transaction, the director directly owned 5,126,891 shares in the company, valued at $76,903,365. This represents a 35.15% increase in their position. The SEC filing for this purchase provides additional information. Insiders bought a total of 3,796,040 shares of company stock valued at $48,699,065 over the last 90 days.
About Electra Therapeutics
Electra Therapeutics, Inc. (NASDAQ: ETRA) is a clinical-stage biotechnology company focused on developing antibody-based medicines for diseases driven by abnormal immune-cell activity. The company’s approach is designed to selectively eliminate or modulate disease-causing immune cells while preserving healthy immune function. Electra’s lead investigational product is ELA026, an antibody targeting SIRPα, a protein involved in immune-cell signaling. The company is evaluating ELA026 in immune-mediated diseases, including systemic sclerosis and other conditions in which macrophages and related immune cells may contribute to disease progression.
Featured Stories
- Five stocks we like better than Electra Therapeutics
- Checkmate for AI Chips? NVIDIA’s Crisis Opens the Board
- Can NVIDIA Maintain Its Momentum Without Huang?
- Six Flags Lost $366 Million in Q3—Its Insiders Just Went Shopping
- What Went Wrong With Amprius Technologies’ Q3? Less Than You’d Think
Receive News & Ratings for Electra Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Electra Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
